gene and clinically characterized by dementia and ataxia. Cerebral amyloid and pre-amyloid deposits of two unrelated molecules (ADan and Aβ), absence of compact plaques, and neurofibrillary degeneration indistinguishable to that observed in Alzheimer's disease (AD) are the main neuropathological features of the disease. Biochemical analysis of extracted amyloid and pre-amyloid species indicates that as the solubility of the deposits decrease, the heterogeneity and complexity of the extracted peptides exponentially increase. Non-fibrillar deposits were mainly composed of intact ADan1-34 and its N-terminally modified (pyroglutamate) counterpart together with Aβ1-42 and Aβ4-42 in ~1:1 mixture. The posttranslational modification, glutamate to pyroglutamate, was not present in soluble circulating ADan. In the amyloid fractions, ADan was heavily oligomerized, highly heterogeneous at the N-and C-terminus and, when intact, its N-terminus was posttranslationally modified (pyroglutamate) while Aβ was mainly Aβ4-42. In all cases, the presence of AβX-40 was negligible, a surprising finding in view of the prevalence of Aβ40 in vascular deposits observed in sporadic and familial AD, Down's syndrome and normal aging. Whether the presence of the two amyloid subunits is imperative for the disease phenotype or just reflects a conformational mimicry remains to be elucidated; nonetheless a specific interaction between ADan oligomers and Aβ molecules was demonstrated in vitro by ligand blot analysis using synthetic peptides. The absence of compact plaques in the presence of extensive neurofibrillar degeneration strongly suggests that compact plaques, fundamental lesions for the diagnosis of AD, are not essential for the mechanism of dementia.
Neuropathologically, FDD shares several features with Alzheimer's disease (AD), among them widespread cerebrovascular amyloidosis, parenchymal amyloid and pre-amyloid lesions and neurofibrillary degeneration (4, 5) . Vascular and perivascular amyloid, parenchymal pre-amyloid lesions, as well as scarce neuritic plaques in the hippocampus are mainly composed of ADan peptides (4) . ADan deposits co-localize with dystrophic neurites surrounding the plaques and with neurofibrillary tangles immunoreactive with hyperphosphorylated tau antibodies. As judged by their paired helical filaments ultrastructure, their reactivity in immunohistochemical analysis and their hyperphosphorylated tau pattern in western blot analysis, these tangles are strikingly similar (if not identical) to those present in AD (5) . Surprisingly, detailed anti-Aβ immunohistochemical survey of different brain areas from all FDD available autopsy cases [three family members from different generations including the case analyzed in the present study (5) ] unequivocally identified Aβ co-deposited with ADan mainly in vascular and perivascular amyloid lesions although in a smaller scale the codeposition was also observed in parenchymal preamyloid deposits (5) . The fact that Aβ codeposition was a constant feature of all three FDD cases available argues against a coincidental nonspecific interaction between two hydrophobic peptides. FDD patients are carriers of a genetic defect in the coding region of the BRI2 gene located in the long arm of chromosome 13. The wild type BRI2 gene (also known as ITM2B) encodes a 266-residues type II single-spanning transmembrane protein (BRI2) (6) (7) (8) which under normal conditions is proteolytically processed by a furin-like protease that produces a single cleavage between Arg 243 and Glu
244
, releasing a C-terminal 23-residues peptide (9) . In patients affected with FDD, a decamer duplication insertion (TTTAATTTGT) between codons 265 and 266 in the BRI2 gene 3' (just one codon before the normal stop codon 267), produces a frame-shift that eliminates the stop signal and generates a longer-than-normal precursor, namely ADanPP. Furin-like proteolytic processing of ADanPP at the same Arg 243 -Glu 244 peptide bond results in the release of a 34 amino acids-long C-terminal peptide ADan which deposits in the form of amyloid fibrils in different brain regions of FDD patients, particularly in limbic structures (4) . The ten-nucleotide duplication insertion observed in FDD patients is not the only BRI2 genetic defect that is linked to a neurodegenerative disorder. A single point mutation at the stop codon of the same gene was previously found to be associated with familial British dementia (FBD) (6) . This early-onset disorder, clinically characterized by progressive dementia, cerebellar ataxia and spastic paraparesis, was first described by Worster-Drought et al. in 1933 as a familial presenile dementia with spastic paralysis (10) (11) (12) (13) . The neuropathology of FBD is remarkably similar to that of FDD and AD, particularly in regard to the presence of neurofibrillary tangles ultrastructurally composed of classical paired helical filaments (14, 15) . As in FDD, the stop to Arg point mutation in FBD also eliminates the BRI2 stop codon and generates a longer-than-normal precursor ABriPP. FBD amyloid deposits in the form of cerebral amyloid angiopathy, pre-amyloid lesions and amyloid plaques are composed of ABri, an amyloid subunit that is also generated by furin proteolytic processing and shares 100% identity with ADan in its first 22 amino acids but that is completely different in its 12 C-terminal residues (6) . Interestingly and in spite of the similarities between FDD and FBD, detailed immunohistochemical studies never found Aβ co-localized with ABri deposits (15, 16) . We describe herein the isolation and biochemical characterization of ADan and Aβ species deposited in both, vessels and parenchymal FDD lesions. Non-fibrillar pre-amyloid lesions were strikingly less complex than their fibrillar counterparts, poorly oligomerized, only partially post-translationally modified and minimally proteolytically degraded. Peptides ending at residue 42 constituted the main Aβ species in both, amyloid and pre-amyloid deposits. Surprisingly, and against the dogma that Aβ peptides ending at residue 40 are always the main components of cerebrovascular lesions in Aβ-related cerebral amyloidosis, AβX-42 species were the predominant Aβ components in FDD deposits. Of note, a specific interaction between synthetic ADan and AβX-42 peptides was demonstrated by ligand blot analysis, pointing to this peptidepeptide interaction as the potential mechanism for their co-localization in vivo.
EXPERIMENTAL PROCEDURES
Materials -Mouse monoclonals 4G8 (anti-Aβ17-24) and 6E10 (anti-Aβ1-17) were purchased from Signet Laboratories (Dedham, MA); mouse monoclonal 6F/3D (anti-Aβ8-17) was from Dako Corp. (Carpinteria, CA); mouse monoclonal AT8 (anti-tau phosphorylated Ser202/Thr205) was from Innogenetics (Gent, Belgium). Rabbit polyclonals anti-Aβ40 and anti-Aβ42 antibodies were obtained from Biosource International (Camarillo, CA). Rabbit polyclonal antibodies anti-ADan (Ab5282, raised against ADan C-terminal amino acids [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] and anti-ABri (Ab338, raised against ABri Cterminal amino acids [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] were prepared in our laboratory (4, 6) and the IgG fractions further purified using Gamma-bind G Sepharose (Amersham Bioscience, Piscataway, NJ) using the manufacturer's standard protocol. Paramagnetic beads coated with anti-rabbit and anti-mouse IgG (Dynabeads M-280) were from Dynal Biotech (Brown Deer, WI). Micro reverse-phase chromatography tips (Zip-Tip C4) were purchased from Millipore (Billerica, MA). SDS-removal reagent SDS-OUT was from Pierce (Rockford, IL). Chemicals were from Sigma (St. Louis, MO). Complete protease inhibitor cocktail was purchased from Roche (Indianapolis, IN). Protein content was measured by the Bicinchoninic/BCA Protein assay (Pierce) employing bovine serum albumin as standard. Synthetic peptides Aβ1-42 (DAEFRHDSGYEV HHQKLVFFAEDVGSNKGAIIGLMVGGVVIA), Aβ4-42 (FRHDSGYEVHHQKLVFFAEDVGSN KGAIIGLMVGGVVIA), ADan1-34 (pEASNCFA IRHFENKFAVETLICFNLFLNSQEKHY) and ABri1-34 (pEASNCFAIRHFENKFAVETLICSR TVKKNIIEEN), the last two featuring N-terminal pyroglutamate and internal disulphide bonds between cysteine residues at positions 5 and 22, were synthesized at the W. M. Keck Facility at Yale University using N-tert-butyloxycarbonyl chemistry, purified by reverse phase-high performance liquid chromatography, their molecular mass corroborated by Matrix-Assisted Laser Desorption / Ionization Time-of-Flight (MALDI-TOF) mass spectrometry, and their concentrations assessed by amino acid analysis.
Clinical data -Frozen brain tissue was available from a male patient who developed blurred vision, nystagmus, positive Romberg's sign and mild memory loss at the age of 25. He underwent bilateral vitrectomy few years later. Transient ischemic attacks occurred at the age of 31. After the development of double vision, ataxia and dementia with threatening behavior, he died at the age of 43 from bronchopneumonia (5) . In this patient, the TTTAATTTGT decamer insertion at codon 265 of the BRI2 gene, characteristic of FDD, was previously confirmed and reported (4) and its ApoE genotype, tested as described below, was found to be ε4/ε3.
Immunohistochemistry -Immunohistochemical investigations were carried out in three previously reported cases of FDD (5) using 7 µm thick sections of formalin fixed paraffin embedded tissue samples. The antibodies used included antiADan polyclonal 5282 (1:2,000), anti-Aβ monoclonal 6F/3D (1:100), and the anti-tau monoclonal AT8 (1:600) recognizing phosphorylated Ser202/Thr205. For confocal microscopy, 20 µm tissue sections were prepared for double staining with the 5282 and 6F/3D antibodies. Tissue sections were pre-treated with 99% formic acid (FA) and pressure cooker in citrate buffer. Sections were initially incubated with the 5282 antibody followed by the appropriate secondary antibody and ABC complex (Dako). Antibody 5282 binding was visualized by applying the tetramethylrhodamine signal amplification kit (PerkinElmer Life and Analytical Sciences, Boston, MA). This step was followed by incubating the sections with the 6F/3D antibody overnight, treating with the appropriate secondary antibody and the ABC complex. Antibody binding was visualized with the fluorescein signal amplification kit (PerkinElmer Life and Analytical Sciences). A Leica TCS SP confocal microscope running TCS NT control software or a Leica DMRE upright microscope using a 3 channel scan head and Argon/Krypton laser were used for the confocal studies.
Sequential tissue fractionation -Leptomeningeal vessels and frontal cortex were used for the biochemical studies described below. Frontal cortex was further dissected into gray and white matter while large vessels were separately analyzed. The extraction strategy took advantage of the differential solubility properties of preamyloid [usually poorly soluble in 10 mM phosphate buffer, pH 7.4 containing 2.7 mM KCl and 137 mM NaCl (PBS) but soluble in 2% sodium dodecyl sulphate (SDS)] and amyloid structures (soluble in 70-98% FA). Samples (typically 2.5 g of gray matter) were homogenized in 12.5 ml of cold PBS containing 2X protease inhibitor cocktail (Complete) using a Douncer glass homogenizer immersed on ice. After homogenization, small vessels were collected by filtration through a 70 µm nylon mesh, combined with the dissected leptomeningeal vessels (typical yield: ~250 mg of vessels per 2.5 g of gray matter) and further extracted as a vessels fraction (12.5 ml of PBS-2X protease inhibitors / 250 mg vessels) while the filtrates were subjected to ultracentrifugation in a XL100K ultracentrifuge (Beckman Coulter, Fullerton, CA) using a Beckman 70.1 Ti rotor at 112,000 g for 1 hour at 4°C. The resultant supernatants were analyzed as PBS-extracted fractions and the pellets were resuspended in 20 mM Tris, pH 7.4 containing 2% SDS (BioRad, Hercules, CA) centrifuged as above although raising the temperature to 10°C to avoid SDS crystallization, and the resultant supernatants analyzed as SDS-extracted (pre-amyloid -rich) fractions. Finally, the Congo-red positive SDSinsoluble material enriched in amyloid fibrils was further extracted in 70% (v/v) FA in water, centrifuged at 14,000 rpm using a 5417R microcentrifuge (Eppendorf, Westbury, NY) and the supernatants analyzed as FA-extracted (amyloid) fractions.
Immunoprecipitation experiments -a) For tissueextracted ADan or Aβ peptides: Fifty microliters of paramagnetic beads coated with either goat anti-rabbit IgG or anti-mouse IgG (Dynabeads M-280, Dynal) were allowed to interact with 6 µg of purified IgG from antiserum 5282 or a combination of 3 µg each of 4G8 and 6E10, for the immunoprecipitation of ADan and Aβ respectively. After washing three times in PBS, beads were blocked in 0.1% (w/v) bovine serum albumin in PBS. Antibody-coated beads were incubated with either 20 µl (~4% of the total fraction) of FA-extracted amyloid fraction previously neutralized in ~800 µl of 0.5 M Trisbase pH 11 or 20% of the total volumes of each, PBS-soluble or SDS-extracted fractions. In the case of the SDS-extracted fractions, SDS was mostly removed prior to immunoprecipitation with SDS-OUT sodium dodecyl sulfate precipitation reagent employing supplier's specifications. Elution of the bound material from the beads was performed by different methods, according to the technique used for the studies that followed. For MALDI-TOF mass spectrometry analysis, beads were subsequently washed three times with PBS, three times with water, and the bound peptides eluted in 5 µl of a 4:4:1 mixture of isopropyl alcohol-water-formic acid (17) . For western blot analysis, beads were suspended in 20 µl of TrisTricine SDS sample buffer (BioRad) containing 10% (v/v) β-mercaptoethanol (Sigma) and directly applied onto the 16% Tris-Tricine gels for SDS-PAGE analysis (17) . In some cases, 5 µl of 1M dithiothreitol (Sigma) was used for sample reduction instead of β-mercaptoethanol. To verify the existence of peptide-peptide interactions between Aβ and ADan, immunoprecipitation experiments using either anti-ADan or anti-Aβ antibodies were carried out in SDSextracts from cerebral vessels using the same immunoprecipitation protocol described above. Samples immunoprecipitated with the mixture of 4G8 plus 6E10 anti-Aβ antibodies were probed in western blot analysis with anti-ADan antibody (Ab5282) and conversely, samples immunoprecipitated with anti-ADan antibody were probed for Aβ with either a mixture of 4G8 plus 6E10, anti-Aβ40 or anti-Aβ42 antibodies. Immunoreactivity was detected by chemiluminescence, as described below. b) For circulating sADan: Plasma from two carriers of the FDD genetic defect (44 and 24 years-old) as well as from 10 non-carriers were analyzed by immunoprecipitation. Fifty microliters of goat anti-rabbit IgG-coated paramagnetic beads were allowed to interact with antibody 5282, as described (17) . After washing and blocking as before, beads were incubated with 1 ml of a 1:1 dilution of plasma in RIPA buffer (1% Triton X-100 in 50 mM Tris, pH 8.0 containing 150 mM NaCl, 0.5% cholic acid, 0.1% SDS, 5 mM EDTA and Complete protease inhibitor). Bound peptides were eluted for MALDI-TOF mass spectrometry or western blot analysis as described above.
MALDI-TOF analysis -Before mass spectrometry analysis, extracted peptides from PBS-, SDS-, and FA-fractions were further purified by immunoprecipitation, as described above. Due to the abundance of ADan in FA fractions, immunoprecipitation was not necessary for its identification by mass spectrometry. In some cases, FA-extracts were alternatively purified by micro reverse-phase chromatography using Zip-TipC4 according to the manufacturer's protocol utilizing 90% (v/v) acetonitrile -0.1% (v/v) trifluoroacetic acid in water for elution. MALDI-TOF mass spectrometry analysis was performed at the New York University Protein Analysis Facility. Samples were analyzed with 10 mg/ml α-cyano-4-hydroxycinnamic acid in 50% acetonitrile and 0.1% trifluoroacetic acid (Sigma-Aldrich) matrix (feasible for <10,000 Da mass range) on a Micromass TofSpec-2E MALDI-TOF mass spectrometer in linear mode using standard instrument settings (17) . Under these experimental acidic conditions, which also renders non-covalent binding unobservable (18) , mostly monomeric species of ADan and Aβ were detected. Internal and / or external calibration was carried out using human adrenocorticotropic hormone peptide 18-39 (average mass = 2,465.68 Da) and insulin (average mass = 5,733.49 Da) as standards. FindPept tool from the ExPASy Proteomics server (http://us.expasy.org/tools) was used to assign the experimental mass values to specific peptide sequences and to search for the presence of posttranslational modifications.
Western Blot Analysis -Samples from each of the extracts, either before or after immunoprecipitation, were separated on a 16% TrisTricine SDS-PAGE and electrotransfered for 45 min at 400 mA onto polyvinylidene difluoride membranes (Immobilon-P, Millipore) using 10 mM 3-cyclohexylamino-1-propanesulfonic acid (Sigma) buffer, pH 11 containing 10% (v/v) methanol. After blocking in 5% non-fat milk in PBS containing 0.1% Tween20 (Sigma), the membranes were immunoreacted with the following antibodies: anti-ADan 5282 (2 µg/ml), anti-Aβ 4G8 (1 µg/ml), anti-Aβ 6E10 (1 µg/ml), anti-Aβ40 (0.05 µg/ml) or anti-Aβ42 (0.05 µg/ml) followed by either anti-rabbit or anti-mouse horseradish peroxidase-labeled F(ab') 2 (Amersham). Signals were developed with Super Signal (Pierce) and exposed to Hyperfilm ECL (Amersham). To enhance Aβ immunoreactivity, membranes after transfer were boiled in PBS for 5 min (19) before incubation with the specific anti-Aβ antibodies. When necessary for re-probing, membranes were incubated in Restore Western Blot Stripping Buffer (Pierce) for 15 min at room temperature, re-blocked and probed with another antibody.
Ligand Blot Analysis -Five micrograms each of synthetic ADan1-34 and ABri1-34 peptides were separated on a 16% Tris-Tricine SDS-PAGE and electrotransfered onto Immobilon-P membranes as described above. After blocking with 5% non-fat milk in PBS, membranes were separately incubated at 37°C for 3 hours with synthetic Aβ1-42 and Aβ4-42 peptides (1 µg/ml in PBS/milk). Bound Aβ was assessed by overnight incubation at 4°C with a mixture of 4G8 and 6E10 (0.5 µg/ml each in PBS/milk) followed by 1 hour incubation at room temperature with anti-mouse horseradish peroxidase-labeled F(ab') 2 and chemiluminescence detected as above. Fifty nanograms of both ADan and ABri peptides were also subjected to Western blot analysis using a mixture of Ab5282 (2 µg/ml) and Ab338 (1 µg/ml) and used as controls.
Amino Acid Sequence Analysis -N-terminal amino acid sequence analysis of isolated amyloid species extracted in FA was carried out by automatic Edman degradation on a 494 Procise Protein Sequencer (Applied Biosystems). Aliquotes from FA-solubilized amyloid fractions were separated on 16% Tris-Tricine SDS-PAGE, transfered onto Immmobilon-P as described above and visualized with 0.125% (w/v) Coomassie Blue R-250 in 50% (v/v) methanol. Relevant components were excised and N-terminal sequenced.
ApoE genotyping -Genomic DNA was extracted from brain tissue using DNeasy Tissue kit (Qiagen, Valencia, CA) and the ApoE genotyping was performed as described (20) , with minor modifications. Briefly, 244 bp polymerase chain reaction products were generated using reverse primer F4 (5'-ACAGAATTCGCCCCGGCCTGG TACAC-3') and forward primer F6 (5'-TAAGC TTGGCACGGCTGCCAAGGA-3'), digested for 4 hours at 37°C with 20 units of HhaI (Promega, Madison, WI), subjected to electrophoresis on non-denaturing 10% polyacrylamide gels and visualized under ultraviolet light after staining with ethidium bromide. Figure 1 illustrates the extent of ADan deposition ( Figure  1A ) and associated tau pathology ( Figure 1B ) in patients with FDD. As shown in panel A, ADan forms loose, ill-defined parenchymal diffuse (preamyloid) plaques (double arrow) and deposits in blood vessel walls (arrow) in FDD. The parenchymal lesions are usually Thioflavin S / Congo red-negative and ultrastructurally appear as mostly amorphous (non-fibrillar) electron-dense material with sparse fibrils, while the vascular deposits are of amyloid nature. The presence of Aβ, sometimes co-localizing with ADan deposits, was previously localized immunohistochemically in three affected family members belonging to different generations (5) and is further illustrated below.
RESULTS

FDD main histopathological features -
Soluble ADan is present in the blood of carriers of the FDD genetic defect -Western blot analysis of immunoprecipitated plasma samples obtained from 2 carriers of the FDD genetic defect revealed the presence of an ~4 kDa component ( Figure 2A ) immunoreactive with Ab5282 (specific for the 12 C-terminal amino acid residues of ADan, a fragment not existent in the normal population). Soluble ADan was consistently monomeric in SDS-PAGE; in mass spectrometry, its m/z experimental value rendered a single peak of 4,063.4 ( Figure 2A ) in good agreement with the expected mass of 4063.6 corresponding to the fulllength peptide bearing glutamate at the N-terminus and a single disulphide-bond between cysteine residues 5 and 22. Soluble ADan was not detected in plasma samples from non-carriers of the disease (n=10) using identical experimental conditions (not shown).
Intact and N-terminally post-translationally modified ADan are predominant components of pre-amyloid and amyloid deposits -FDD parenchymal samples and cerebral vessels were sequentially extracted in PBS, 2% SDS and 70% FA and analyzed for the presence of ADan species by mass spectrometry and western blot. In some cases, particularly in samples extracted with FA which were more abundant, we also conducted Nterminal amino acid sequence analysis. As expected, the vast majority of ADan was recovered from the amyloid extracts; however, using a combination of immunoprecipitation and western blot / mass spectrometry, it was also possible to detect ADan species in all other fractions. Compared with the plasma specimens there were noticeable differences in terms of degree of aggregation and N-terminal posttranslational modifications. Figure 2B illustrates ADan species in PBS-extracts. PBS-soluble ADan was mainly monomeric with some dimers barely visible in both parenchymal and vascular fractions, as indicated by the western blot. Mass spectrometry revealed that these fractions were composed of a mixture of two ADan species differing in 18 mass units 4045.2 for parenchyma / 4045.3 for vessels (expected 4045.6) and 4063.5 for parenchyma / 4062.7 for vessels (expected 4063.6), a difference equivalent to the mass of one molecule of water and likely corresponding to ADan-pE and ADan-E species in a ~60:40 ratio (see below). Since parenchymal and vessels fractions were representative of the same amount of original tissue, it is apparent by the western blot analysis that the PBS-soluble ADan species in FDD are more abundant in vessels than in brain parenchyma. Similar results were obtained with the SDSextracted fractions, although as judged by the monomers:dimers ratio, samples had less tendency to remain monomeric. As indicated in Figure 2C , ADan was predominantly dimeric in parenchymal extracts (ratio monomers:dimers ~1:3) while in vascular extracts the monomeric form was still predominant (ratio monomers:dimers ~5:1). By mass spectrometry analysis, both extracts contained the same two ADan species seen in the PBS-extracts and differing in 18 units of mass in a similar 60:40 ratio. The experimental masses, 4043.6 for parenchyma /4045.6 for vessels and 4062.0 for parenchyma / 4063.6 for vessels were in good aggreement with the expected masses of the post-translationally modified ADan-pE (4045.6) and the wild-type ADan-E (4063.6), with a single disulphide-bond between cysteine residues 5 and 22. Analysis of the FA-extracts revealed more complexity in terms of composition and degree of aggregation than the other fractions. The interpretation of the mass spectrometry analysis was also more challenging due to the additional presence of mono-, di-, and tri-formylated species, likely on lysine and/or serine residues (21), artifactually generated during the extraction procedure. As illustrated in Figure 3 , both parenchymal and vascular lesions were composed of a heterogeneous mixture of post-translationally modified and N-and C-terminally truncated ADan species. The predominant components were ADan1-33pE, ADan1-28pE and ADan1-34pE although the presence of ADan3-28, ADan1-27pE, ADan1-30pE, ADan3-33, ADan3-34, ADan 1-33E and ADan 1-34E was consistently demonstrated (See Figure 3A , mass spectrometry spectra and Table) . This ample heterogeneity was also reflected in the extensive ADan aggregation observed in SDS-PAGE when compared with PBS-and SDS-extracts. Monomers, dimers, trimers and larger aggregates were clearly highlighted in parenchymal FA-extracts. The aggregation pattern was even more prominent in FA-extracts obtained from vessels ( Figure 3B ) in which the bulk of amyloid deposition occurs in FDD patients. The abundance of FA-soluble ADan species compared with their water-soluble counterparts was not only reflected in the intensity of the immunoreactivity of both parenchymal and vascular extracts but in the amount of protein necessary to visualize ADan species (1,500-fold and 5,000-fold more protein was required for the PBS-and SDS-extracts of parenchyma and vessels, respectively, than for the FA-fractions). The N-terminal heterogeneity of ADan peptides in FA-extracted fractions was confirmed by Nterminal sequence analysis in both parenchymal and vascular extracts. The minor sequences retrieved, SNXFAIR… and EASNXF…, corresponded to ADan starting at positions 3 and 1 respectively, in ~3:1 ratio. Yield calculations revealed that these sequences represented about 10-15% of the material loaded into the sequencer cartridge, indicating that 85-90% of the material did not undergo Edman degradation and consistent with the presence of cyclic N-terminal pyroglutamate. These results are in agreement with the relevance of the N-terminal pyroglutamate ADan species identified by mass spectrometry (Figure 3 ) and with previous published data in leptomeningeal vessels (4).
Aβ42 colocalizes with ADan parenchymal and vascular lesions -All parenchymal and vascular extracts previously analyzed for ADan (PBS-, SDS-and FA-extracts) were also evaluated for the presence of Aβ species via immunoprecipitation/ mass spectrometry and immunoprecipitation/ western blot using four different anti-Aβ antibodies: 4G8 (anti-Aβ17-24), 6E10 (anti-Aβ1-17), and the C-terminal specific anti-Aβ40 and anti-Aβ42. As illustrated in Figure 4 (panels A and B), Aβ species were detectable in PBS-extracts from parenchyma and vessels fractions. Parenchymal extracts were immunoreactive with antibodies 4G8, 6E10 and anti-Aβ42 but not with anti-Aβ40. Monomers and dimers of AβX-42 were observed with an estimated monomers:dimers ratio of ~1:2 (Panel A). Although low signal was retrieved in the mass spectrometry there was a peak with a mass suspected to correspond to the fragment Aβ4-34 (experimental 3473.5; expected 3472.9); no clear peaks of AβX-42 were detected (panel A and Table) . Vascular extracts, on the other hand, rendered a more defined picture both at the western blot and mass spectrometry levels. As indicated in panel B, Aβ species were immunoreactive with all antibodies, including anti-Aβ40. Several differences were spotted when compared with the parenchymal counterparts: i) the signals for monomers and dimers were stronger, ii) Aβ40 immunoreactivity (although not strong) was seen with dimeric species, a signal not detected in parenchymal fractions, and iii) the monomeric component detected by 6E10 and anti-Aβ42 was clearly composed of two bands of very close molecular mass. As judged by mass spectrometry analysis, the major Aβ species in the sample were Aβ1-42, Aβ4-42, and Aβ1-40, (Panel B and Table) , being the latter a minor component. Interestingly, the immunoprecipitation procedure using a mixture of 4G8 + 6E10 antibodies prior to the MALDI-TOF analysis also retrieved fulllength ADan (both ADan-pE and ADan-E), suggestive of a protein-protein interaction between both peptides (see below). The identification of Aβ4-42 and Aβ1-42 differing in 315 units of mass strongly argues that these species are the components of the double band with the electrophoretic mobility of the monomeric species observed in the 4 kDa molecular mass of the western blot with 6E10 and anti-Aβ42 (Panel B).
When the SDS-extracts were analyzed by the same procedures, the results obtained were similar to those in the PBS-extracts although i) under the same protein load the immunoreactive signals were stronger suggesting a relative enrichment on Aβ species, and ii) the dimeric forms were more relevant.
Parenchymal extracts were immunoreactive with 4G8, 6E10 and anti-Aβ42, but not with anti-Aβ40 (Panel C Table) . The double peaks obtained in this sample originate in the presence of Aβ peptides bearing oxidized Met35 (Met sulfoxide; +16 mass units), most probably a technical artifact due to the use of formic acid to process this sample for mass spectrometry. In vitro pre-treatment of synthetic Aβ40 and Aβ42 with formic acid produced similar effect (not shown). Aβ species in vessel extracts were immunoreactive with all the antibodies tested (Panel D). As curiously observed with the PBSfractions (Panel B), i) Aβ40 immunoreactivity was also limited to dimeric species, and ii) the monomeric component detected by 6E10 and anti-Aβ42 was also composed of two bands of very close molecular mass (as shown in panels B and C). In general terms, the dimeric species were more prominent than in the PBS-fractions. Mass spectrometry identified Aβ1-42 and Aβ4-42 as the major components whereas Aβ1-40 was a minor constituent of the extract. As illustrated above with the PBS-fractions, immunoprecipitation with the anti-Aβ antibodies also retrieved a minor amount of full-length ADan (Panel D). Formic acid retrieved mainly polymerized Aβ species in both, parenchymal and vascular lesions. As illustrated in Figure 5A , parenchymal extracts were immunoreactive with 4G8, 6E10 and anti-Aβ42 antibodies but were not recognized by anti-Aβ40. Aβ species were mainly dimeric although small proportion of higher oligomers were visible with both, 4G8 and anti-Aβ42. When the same sample was analyzed by mass spectrometry, the most prominent signal corresponded to an experimental m/z of 4200.0, consistent with the theoretical protonated mass of 4199.8 for Aβ4-42.
Both, Aβ1-42 and Aβ1-40 were also present in the sample, although Aβ1-40 was a minute contributor to the composition of the FA-extract, data consistent with the lack of immunoreactive signal in the western blots. Two additional peaks differing in +16 and +28 mass units with Aβ4-42 were also observed. Both experimental masses matched the expected values for Aβ4-42 (Met sulfoxide) and Aβ4-42 (formylated). Since samples were exposed to FA during the extraction procedure and prior to the mass spectrometry analysis, these Aβ derivatives may well represent undesirable secondary products of the speciment treatment rather than actual post-translationally modified components present in the lesions. Alternatively, these oxidized Aβ42 species may represent existent in vivo neurotoxic subproducts of oxidative stress, as previously proposed (22) . Vascular FA-extracts showed a similar pattern than the parenchymal counterpart although Aβ species seemed to be present in a slightly higher degree of oligomerization. As indicated in Figure  5B , the vessels extracts were immunoreactive with all anti-Aβ antibodies tested; 4G8 and anti-Aβ42 reacted with dimers and larger oligomers whereas anti-Aβ40 was bearily immunoreactive with the dimeric species. Mass spectrometry analysis of the same fractions revealed that Aβ1-42 and its Nterminal truncated derivative Aβ4-42 were the main Aβ species with experimental masses matching their theoretical values whereas minor Aβ4-42 oxidized and formylated derivatives were also detected ( Figure 5B and Table) . As observed with ADan, the abundance of FA-soluble Aβ species compared with their water-soluble counterparts was reflected in the intensity of the immunoreactivity of both parenchymal and vascular extracts and in the amount of protein required to visualize them (1,500-fold and 5,000-fold more protein for the PBS-and SDS-extracts of parenchyma and vessels, respectively, than for the FA-fractions). Confocal microscopy demonstrates co-localization but not complete overlap between ADan and Aβ staining of parenchymal lesions and blood vessels ( Figure 6 , panels A-C), suggesting co-deposition on many areas. In order to further test whether the partial co-localization of Aβ and ADan was related at least in part to a specific peptide-peptide interaction we conducted co-immuno-precipitation experiments with tissue extracts and ligand-blot analysis with synthetic peptides. As illustrated in Figure 6D for vascular SDS-extracts, a combination of anti-Aβ antibodies 4G8 and 6E10 retrieved a mixture of monomeric and dimeric ADan immunoreactive with Ab 5282 (left panel). However, in the reverse experiment with the same vascular SDS-extracts, anti-ADan antibodies retrieved dimeric Aβ that was reactive with the mixture 4G8 plus 6E10, with anti-Aβ42, but not with anti-Aβ40 antibodies (right panel). Similar results were obtained with PBS-extracts (data not shown). FA-extracts, on the contrary, rendered negative results in spite of the high concentration of both ADan and Aβ, likely indicating that the interaction is susceptible to dissociation at low pH as previously seen in other protein-protein interactions, i.e. Aβ-apolipoprotein J (23).
To verify the specificity of the ADan-Aβ interaction, ligand blot analysis using synthetic ADan and Aβ homologues and synthetic ABri as a control was conducted in vitro. As indicated in Figure 7 , specific binding of Aβ4-42 and Aβ1-42 (the main Aβ species found in FDD lesions) to ADan oligomers (particularly dimers) was clearly evident whereas no interaction was observed with ADan monomers in spite of their abundance. In contrast to ADan, neither monomers nor oligomers of ABri peptides show binding interaction with either Aβ4-42 or Aβ1-42.
DISCUSSION
Immunohistochemical analysis of FDD cases indicate that vascular amyloid and parenchymal pre-amyloid deposits of ADan and Aβ co-exist in the absence of compact plaques. The ADan/Aβ composition of both lesions were analyzed by western blot, mass spectromery and amino acid sequence analysis after tissue dissection and separation of vessels from parenchymal specimens. Accordingly, water-based solutions in the absence and presence of low concentrations of the anionic detergent SDS were used to extract mainly nonfibrillar components whereas formic acid extraction was necessary to solubilize and analyze fibrillar deposits. Our biochemical data (Figures 2-5) show that FDD non-fibrillar and fibrillar lesions are heterogeneous mixtures of various ADan and Aβ species. The peptide composition, degree of oligomerization, predominant amyloid subunits, extent of post-translational modifications and magnitude of N-and C-terminal proteolytic degradations reflect the complexity of the lesions. In general terms, non-fibrillar deposits appeared less complex than the fibrillar counterparts, perhaps reflecting early intermediate states of the fibrillization process. The degree of oligomerization was limited only to dimeric forms whereas the diversity of the ADan and Aβ peptides was also highly restricted. ADan species were limited to the non-degraded full-length ADan1-34, although in contrast to what is seen in plasma, ~60% of these molecules were found to be posttranslationally modified at their N-terminus. Cyclic pyroglutamate was previously observed in other brain amyloids, i.e. ABri in FBD (6) and in truncated forms of the Alzheimer's Aβ peptide (24) (25) (26) as well as in some hormones and neuropeptides including neurotensin, thyrotropin-, and gonadotropin-releasing hormones in which their biological activities largely depend on the existence of the N-terminal pyroglutamate (27) . Although the final pyroglutamate product is the same, neuropeptides and amyloids differ in the amino acid that serves as a substrate for the posttranslational modification. In many neuropeptides and peptide hormones the N-terminal posttranslational modification occurs at a glutamine residue and the cyclization involves the nucleophilic attack of the α-amino group on the amidated carboxyl group and the release of NH 3 catalyzed by glutaminyl cyclase at neutral pH (28, 29) . In contrast, few examples are known for the post-translational modification from glutamic acid to pyroglutamate, which involve the loss of a molecule of water instead of deamination. Among them are bovine and ovine β-lipotropin and joining peptide derived from the proteolytic processing of their common precursor pro-opiomelanocortin (30,31), ABri amyloid in FBD (6) , and the Aβ Nterminal truncated derivatives Aβ3-XpE and Aβ11-XpE in AD (24, 25, 32) . The process has been demonstrated in Aplysia neurons (33) and is not exclusive to the brain, since a similar conversion has been identified in peripheral organs affected with amyloid deposition in FBD (17) . Whether the same glutaminyl cyclase is responsible for the dehydration process in all these cases remains known. Since this N-terminal modification was not detected in the soluble circulating ABri or ADan species, it is conceivable that cyclization occurs in situ at the sites of deposition. The Aβ peptides found in the non-fibrillar deposits were also restricted in diversity. Aβ1-42 and the N-terminally truncated Aβ4-42 were the major species in an ~1:1 ratio whereas Aβ1-40 and Aβ derivatives ending at position 34 were minor component of the extracts (Figure 8 ). Although predominant species ending at position 42 were expected in the parenchymal extracts, their abundance in vascular components was surprising. Limited published studies indicate that Aβ-related parenchymal pre-amyloid lesions are enriched in species ending at position 42. The α-secretase fragment Aβ17-42, in particular, was previously identified as the main component of pre-amyloid lesions in AD (34), Down's syndrome (35) and aged dogs (36) , being Aβ1-42 and Aβ4-42 minor components in the last 2 cases. In FDD extracts, Aβ17-42 was not detected and although it could be argued that the present extraction conditions were milder than those previously reported (2% SDS vs. 15% SDS) thereby precluding the retrieval of Aβ17-42, this fragment was also undetected in the subsequent formic acid extracts. Although not through biochemical studies, the existence of other Aβ species were also previously identified in preamyloid lesions based on classical immunohistochemical stainings and their immunoreactivity with specific antibodies. Accordingly, Aβ1-42 and Aβ3-42pE were reported to be major components in AD, Down's syndrome and normal aging preamyloid lesions whereas antibodies recognizing position 17 were only weakly positive (37) . Anti-Aβ42 immunoreactivity was also found prevalent in parenchymal pre-amyloid deposits in the Dutch variant of familial AD (38) . ADan and Aβ species extracted with formic acid from amyloid deposits were more heterogeneous. ADan was fully post-translationally modified at the N-terminus (pyroglutamate), partially N-and C-terminally degraded at positions 3, 28 and 33, and heavily oligomerized (Figures 3 and 8) , whereas Aβ, still mainly composed of Aβ1-42 and Aβ4-42 (with negligible Aβ1-40), showed more N-terminal degradation (ratio Aβ4-42:Aβ1-42 approximately 9:1) and higher degree of oligomerization ( Figures 5 and 8) . Whether extensive proteolytic degradation and heavier oligomerization reflect critical necessary steps in the process of ADan amyloid formation or simply a futile cellular effort to end and clear the formation of fibrillar deposits is still under investigation. In the case of Aβ, the N-terminal degraded Aβ4-42 is known to have a faster aggregation kinetics than the intact Aβ1-42 (39) . The fact that the ADan proteolytic fragments were not detected in blood and that circulating soluble ADan peptides differ from the deposited homologues in that they consistently lack the chemically irreversible pyroglutamate modification at the N-terminus is a clear indication that the circulating species do not represent a clearance mechanism from the cerebral deposits. In this sense, we previously reported similar findings for the soluble and deposited ABri species in FBD (17) . As summarized in Figure 8 , the proteolytic degradation of ADan and Aβ reflects the activity of more than a single enzyme. A potential candidate for the C-terminal de-tyrosination of ADan is cathepsin A (carboxypeptidase A) (40) which is widely distributed in lysosomes and has broad specificity, releasing the C-terminal amino acid at optimum pH of 4.5-6.0. The cleavage at ADan Ala 2 -Ser 3 peptide bond seems to be catalyzed by a dipeptidyl-peptidase, in a similar fashion than deposited ABri amyloid in FBD (6) . It is interesting to note that no proteolytic processing of ADan molecules was detected between cysteine residues 5 and 22, suggesting a protective effect of the disulphide bond as reported for other proteins (41-43). Degradation of Aβ at peptide-bond Glu 3 -Phe 4 may result from either neprilysin or insulysin (insulindegrading enzyme) degradation, as previously reported in Aβ-related disorders (44, 45) . However, these enzymes are not exclusive for the Glu 3 -Phe 4 peptide bond processing and are known to cleave Aβ at several other sites, generating degradation fragments that were not detected in FDD extracts. Another probable enzyme to consider is tripeptidyl-peptidase I, a lysosomal protease known to cleave the Glu 3 -Phe 4 peptide bond in vitro and a known component of amyloid plaques (46, 47) . It is important to note that the same proteolytic activity also results from the use of bacterial collagenase I (EC 3.4.24.3; http://us.expasy.org/enzyme). Using synthetic Aβ40 and Aβ42 as substrates, this enzyme was able to efficiently cleave both peptides at Glu 3 -Phe 4 and Leu 34 -Met 35 bonds in in vitro experiments (unpublished observations). Although collagenase I has been commonly used in amyloid purification protocols to increase the yield of the extracted fibrils (48-52), we purpously avoided its use in our FDD isolation protocol in order to prevent anwanted artifacts. In sporadic and familial AD as well as in other Aβ-related disorders, amyloid deposits in cerebral vessels are primarily constituted of fibrillar forms of Aβ40 although the presence of Aβ42 in detectable amounts is considered a common finding in these lesions [reviewed in (53) ]. Similarly, in the various transgenic models of Aβ deposition, Aβ40 is the main component of vascular deposits (54) (55) (56) including the recently published APP-Dutch mouse (57) . The fact that the main Aβ components of the vascular FDD lesions were AβX-42 species was somehow an unexpected finding of still unknown connotations for the disease pathogenesis. The importance of Aβ42 for the formation of vascular deposits is also highlighted by the recent report on the chimeric BRI-Aβ42 mice, which selectively overproduce Aβ42 but not Aβ40, and the demonstration of extensive Aβ42 cerebral amyloid angiopathy whereas the BRI-Aβ40 chimeric mice overproducing Aβ40 did not show overt amyloid pathology, questioning the importance of Aβ40 in the initiation of vascular amyloid deposits. (58) . It is also not clear whether the co-localization of ADan with Aβ reflects important aspects of the mechanism of amyloidogenesis or simply a conformational mimicry, by which one molecule induces another to adopt a similar structural conformation favoring oligomerization. In this sense, dimers (not monomers) of Aβ molecules were retrieved in co-immunoprecipitation experiments from tissue extracts and Aβ1-42 and Aβ4-42 bound to ADan dimers and higher oligomers (not monomers) in ligand blot analysis, suggesting conformational specificity. It is important to note that Aβ was neither detected in parenchymal or vascular ABri deposits in FBD (15, 16) nor identified as an Aβ ligand in the ligand-blot analysis shown in Figure 7 in spite of being ABri and ADan molecules identical in their 22 N-terminal residues. Mounting evidence indicate that plaque burden correlates poorly with degree of dementia and that soluble oligomers rather than the final amyloid fibrils are the harmful Aβ species (59) (60) (61) (62) . This viewpoint is supported by the two hereditary disorders FBD and FDD (collectively known as Chromosome 13 Dementias) and by the Iowa variant of familial AD associated with the deposition of the mutant AβD23N (63) . In spite of the structural differences among ABri, ADan and Aβ, absence or limited number of compact plaques and extensive neurofibrillar degeneration with tangles identical to those found in Alzheimer's brains are main features of these disorders. Therefore, not only different amyloid peptides are associated with similar neuropathological changes but these disorders question the importance of compact plaques in the mechanism of neuronal toxicity. Compact plaques are absent in FDD, in the Iowa variant of familial AD, and in certain brain areas in FBD whereas all disorders feature parenchymal pre-amyloid lesions as well as vascular and perivascular deposits and yet, the final clinical outcome of these diseases is AD-like dementia. Thus, if amyloid is of paramount importance in the development of dementia, it is certainly neither exclusive for Aβ nor dependent on the presence of compact plaques. We propose that these disorders are suitable models to study early steps in peptide oligomerization/fibrillization and the role of pre-amyloid and vascular amyloid in the process of neurodegeneration. Aβ species were immunoprecipitated with Dynabeads coated with a mixture of 4G8 and 6E10. Bound peptides were eluted and analyzed either by western blot using a panel of anti-Aβ antibodies (4G8, 6E10, anti-Aβ40, anti-Aβ42) or by MALDI-TOF mass spectrometry as described in Experimental Procedures. PBS-extracted fractions from 500 mg of microvessel-depleted frontal cortex (Panel A) and 50 mg of isolated microvessels and leptomeningeal vessels equivalent to 500 mg of frontal cortex (Panel B). SDSextracted fractions from 500 mg of microvessel-depleted frontal cortex (Panel C) and 50 mg of isolated microvessels and leptomeningeal vessels equivalent to 500 mg of frontal cortex (Panel D). Theoretical average masses and experimental Aβ molecular masses are shown in the bottom table. Notation for the western blot: Mo, monomers; Di, dimers. Peaks of mass spectra indicated by # were present in the negative controls (without brain extracts) and considered to be non-specific. Peaks notated by ¤ were also obtained in negative controls (using brain extracts but uncoated Dynabeads) and considered non-specific. 
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